CanSino Biologics (HKG:6185, SHA:688185) said its new drug application for tetanus vaccine was accepted by the National Medical Products Administration of China, a Thursday bourse filing said.
Tetanus, a severe infectious disease, is caused by Clostridium tetani with a mortality rate reaching 30%-50% with medical intervention while the rate stands at 100% without medical intervention.
The vaccine, developed by the company, is aimed at non-neonatal tetanus prevention. It is safer as it is fermented with an animal-free culture medium, the filing said.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。